Meet the Houston entrepreneur behind the 'Uber of design'

Featured Innovator

Lisa Pope Westerman has created LUCID, a network of architects that's flipping the script on how architecture projects go. Courtesy of LUCID

What if retaining one architecture company gave you access to dozens more? That's the idea behind LUCID, an architecture and design collective that Lisa Pope Westerman, formerly of San Francisco-based Gensler and New York City-based rockwell group, launched in Houston this year.

LUCID is a collective of architects and boutique architecture firms that specialize in at least one of the following property types: hospitality, retail, mixed-use developments, high-rise residential, and wellness developments. When clients retain LUCID as their designer or architect, they're given access to the firms and individual architects who are best suited for the job. Currently, LUCID is composed of roughly 40 total architects coming from several architecture and design firms, including Chicago-based PinPoint Collective, Houston-based gin design group, and New York-based Glen & Co. architecture.

"People have referred to us as 'the WeWork of architecture,' or 'the Uber of design,'" Pope Westerman says. "We think that in 10 years, this is how the world will just be working."

Pope Westerman spoke with InnovationMap about launching LUCID, Houston's unique design community and how the architecture industry continues to innovate.

InnovationMap: When did you start planning LUCID?

Lisa Pope Westerman: I really started thinking about it in beginning of 2018, and working on it middle of 2018, and making sure the initial groups we started with are a good fit. It's been nothing but wonderful. Everyone's smarter than me, and brings such a unique perspective to the group for various reasons. Not everyone is an architect or an interior designer ­– the intent is to be really nimble and flexible. We're bringing a lot of unique specialists. We have branding, graphic design, and a strategy group that is just amazing.

We're looking to, as a group, not just be innovative, but have innovation in all the different types of things [we offer], including our process. We believe that the world of design is going to be much more than visual, and that we really need to be thinking about all the senses, like touch and smell and [hearing]. Just typically, everything's visual, and [the other senses] have been secondary.

IM: How did LUCID find the architects and architecture firms that compose the collective?

LPW: The original of roughly 40 people are people I've worked with over the past 20 years. That's how we got things started. I've basically been involved in every size company imaginable: from a one-man show, to the largest design firm in the world, Gensler. The intent of the model is to create something where there's a parent brand that feels like a very large company, and we're essentially an umbrella, and within us are all the other wonderful boutique specialty brands.

IM: What kinds of architecture firms does LUCID work with?

LPW: Most of the firms affiliated with us are around a dozen people. We find that's the right size of people that are highly specialized, super talented, and able to maintain the [high] quality level.

IM: Tell me a bit about LUCID's business model.

LPW: So, we facilitate everything, and that's how [LUCID] is compensated. So, we essentially facilitate in bringing the companies to the client, which is the business development aspect of things. We collaborate on the client management side, so we're still very involved with the clients and the projects. We carry everybody. We help manage all of it, and all of the companies' [projects]. It's a true collaboration.

People truly believe that by being associated with LUCID, they're going to be able to elevate what they've been doing even more. It's important that the companies that want to be affiliated with LUCID are really interested in that.

IM: Can the architecture firms that are a part of LUCID still do work outside of the LUCID collective?

LPW: All the firms connected to LUCID still do their own business. They haven't folded into LUCID and then given up their brand. The intent is that we're celebrating the brands. We like the diversity.

IM: LUCID is currently working on its first project. What information can you share?

LPW: It's in the hospitality industry, and it is a restaurant, bar, event space, and it's for a private club outside of Houston. We started at the beginning of [2019], and we'll be done at the end of the year.

IM: Did LUCID launch with a fund raise? Are you planning a fund raise?

LPW: The front end is really just a shared passion among the companies and individuals that are connected. Longer term, we are interested in even partnering with investors in creating new and different kinds of projects. There are some other firms out there, but not many, that are starting to do that sort of thing … where [the design firm] collaborates with investors and projects, rather than just being hired on as the designer for a project.

IM: How is the Houston design scene different from design scenes around the world?

LPW: Well, I think it's an exciting time for Houston. Especially in our world of lifestyle design, it's the overarching [theme]. We do everything for lifestyle. In Houston, we're really starting to be at the height of this renaissance of bringing just a higher level of appreciation for design. From a lifestyle standpoint, things have been percolating for a while now.

IM: What's a foundational project you've worked on that taught you an essential lesson about design?

LPW: In terms of my Houston project base, certainly the ExxonMobil project was really impactful, because of the scale of the project and all the different participants in it. We collaborated with several other design firms, both in Houston and out of Houston, and not only design firms, but also globally acclaimed artisans. Just at a worldwide level, the caliber of the clients was amazing. It was an incredible experience because of the scale and the success of it. … It was building a city.

------

Portions of this interview have been edited.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston digital health platform Koda lands strategic investment

money moves

Houston-based advance care planning platform Koda Health has added another investor to the lineup.

The company secured a strategic investment for an undisclosed amount from UPMC Enterprises, the commercialization arm of the University of Pittsburgh Medical Center. The funding is part of Koda's oversubscribed series A funding round that closed in October, according to a release.

"UPMC Enterprises’ investment is a meaningful signal, not just to Koda, but to the broader market," Dr. Desh Mohan, chief medical officer and co-founder of Koda Health, said in the news release. "It validates that health systems are ready to invest in infrastructure that makes advance care planning work the way it should: proactively, at scale, and with the human support that these conversations require. Having UPMC Enterprises as a strategic investor puts us in a unique position to prove what's possible."

Koda has raised $14 million to date, according to a representative from the company. Its series A round was led by Evidenced, with participation from Mudita Venture Partners, Techstars and the Texas Medical Center last year. At the time, the company said the funding would allow it to scale operations and expand engineering, clinical strategy and customer success. The company described the round as a "pivotal moment," as it had secured investments from influential leaders in the healthcare and venture capital space.

Koda Health, which was born out of the TMC's Biodesign Fellowship in 2020, saw major growth last year, as well, and now supports more than 1 million patients nationwide through partnerships with Cigna Healthcare, Privia Health, Guidehealth, Sentara, UPMC and Memorial Hermann Health System.

The company integrated its end-of-life care planning platform with Dallas-based Guidehealth in April 2025 and with Epic Systems in July 2025. It also won the 2025 Houston Innovation Award in the Health Tech Business category. Read more here.

UH med school gets $2M gift and more top Houston innovation news

Trending Topics

Editor's note: The top Houston innovation news of the month is full of fresh funding, with two Texas medical schools receiving major gifts — one of historic proportions. Below are the five most-read InnovationMap headlines from April 16-30, 2026.

UH med school granted $2M gift to offer student scholarships

A new scholarship endowment aims to support students in the University of Houston’s recently established medical school. The University of Houston’s Tilman J. Fertitta Family College of Medicine received a planned estate gift commitment estimated at $2.1 million to establish the Bob Diehl and Teresa Evans Diehl Scholarship Endowment. The scholarship will assist full-time medical students who demonstrate financial need and meet academic standards. Continue reading.

How Houston innovators played a role in the historic Artemis II splashdown

Research from Rice University played a critical role in the safe return of U.S. astronauts aboard NASA’s Artemis II mission this month. Rice mechanical engineer Tayfun E. Tezduyar and longtime collaborator Kenji Takizawa developed a key computational parachute fluid-structure interaction (FSI) analysis system that proved vital in NASA’s Orion capsule’s descent into the Pacific Ocean. The FSI system, originally developed in 2013 alongside NASA Johnson Space Center, was critical in Orion’s three-parachute design, which slowed the capsule as it returned to Earth, according to Rice. Continue reading.

Baylor scientist lands $2M grant to explore links between viruses and Alzheimer’s

A Baylor College of Medicine scientist will begin exploring the possible link between Alzheimer’s disease and viral infections thanks to a $2 million grant awarded in March. Dr. Ryan S. Dhindsa hypothesizes that Alzheimer’s may have some link to previous viral infections contracted by the patient. To study this intriguing possibility, the American Brain Foundation has gifted him the Cure One, Cure Many award in neuroinflammation. Continue reading.

New UT Austin med center, anchored by MD Anderson, gets historic gift

A donation announced April 21 breaks a major record at the University of Texas at Austin. Michael and Susan Dell are now UT Austin's first supporters to give $1 billion. In response, the university will create the UT Dell Campus for Advanced Research and the UT Dell Medical Center to "advance human health," per a press release. Continue reading.

Houston VC funding surged nearly 50% in Q1 2026, report says

Houston saw a jump in VC funding in Q1 2026, fueled by several major investments in clean energy startups. Image via Getty Images

First-quarter venture capital funding for Houston-area startups climbed nearly 50 percent compared to the same time last year, according to the PitchBook-NVCA Venture Monitor. In Q1 2026, Houston-area startups raised $532.3 million, a 49 percent jump from $320.2 million in Q1 2025, according to the PitchBook-NVCA Venture Monitor. However, the Q1 total fell 23 percent from the $671.05 million raised in Q4 2025. Continue reading.

New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”

View All Listings